Loading…
Loading…
Quest Diagnostics beats Q3 earnings and revenue estimates, raises its 2026 outlook on strong testing demand and margin gains, yet shares dip in pre-market trading.
Quest Diagnostics NYSE: DGX reported third-quarter 2026 revenue growth of 10% and adjusted earnings-per-share growth of more than 15%, citing demand across its physician, hospital and consumer channels as well as productivity gains from automation and artificial intelligence. The company raised and narrowed its full-year revenue and earnings outlook.
Quest Diagnostics expects consumer health revenue growth to exceed 30% in 2026. Organic requisition volume increased 14.4% in the third quarter of 2026.
Quest Diagnostics Incorporated (DGX) Q3 2026 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX) on Thursday reported third-quarter adjusted earnings of $3 per share, beating the Wall Street estimate of $2.86.
Quest Diagnostics (DGX) came out with quarterly earnings of $3 per share, beating the Zacks Consensus Estimate of $2.85 per share. This compares to earnings of $2.6 per share a year ago.
Third quarter revenues of $3.10 billion, up 10.0% from 2025, on strong organic revenue growth Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025 Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35 SECAUCUS, N.J., Oct. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third quarter ended September 30, 2026.
Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J.